Blood-pressure drugs and cancer: much ado about nothing?

摘要

For more than 35 years, the risk of cancer has been discussed in relation to high blood pressure. Some case-control studies and post-hoc analyses from prospective intervention trials have suggested that several classes of blood-pressure-lowering drugs were associated with an increased cancer risk. A difficulty with interpretation of these results, however, is that follow-up is only around 2-5 years, which is too short to show an increase in cancer detection.